IL-15RαFc superagonist SHR-1501 with or without bacille Calmette Guerin (BCG) for high-risk non-muscle invasive bladder cancer (NMIBC): A phase 1/2 study. RFS rate in all Pts, % ( 95%CI) 96 (88, 100) ...
ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results